Trial
NCT04143958
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Fabry Disease
Intervention
agalsidase beta (GZ419828)
Why stopped
The Sponsor terminated the study due to recruitment infeasibility without having enrolled any patient.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-07